ABSTRACT
Objective To investigate the effects of NVP-BEZ235 on proliferation and apoptosis of human cholangiocarcinoma(CCA) cell QBC939 in vitro and to reveal the antineoplastic mechanisms of NVP-BEZ235.Methods Human CCA cell line QBC939 was used in this study.Cell apoptosis by NVP-BEZ235 was analyzed using the flow cytometry.Cell growth inhibition by NVP-BEZ235 for 24h 48h 72h by MTT assay.The antineoplastic mechanisms of NVP-BEZ235 for 48h were assessed by western blotting for PARP、Bcl-2、Akt、p-Akt、c-FLIPL and Mcl-1 assay in QBC939 cell.Results NVP-BEZ235 treatment inhibited the proliferation and induced apoptosis of human CCA cell QBC939,which appeared time-dependent and concentration-dependent effects.NVP-BEZ235 reduced protein levels of Mcl-1、c-FLIPL and Bcl-2 and downregulate protein level of p-Akt significantly.Conclusion NVP-BEZ235 inhibited the phosphorylation of Akt.NVP-BEZ235 downregulated Bcl-2、c-FLIPL、Mcl-1 protein level via PI3K/AKT signaling pathway to induce apoptosis and inhibit the proliferation of human CCA cell QBC939.
ABSTRACT
Objective The purpose of this study was to investigate the efficacy and safety of bortezomib +doxorubicin + dexamethasone (PAD) regimen in the treatment of patients with multiple myeloma (MM) . Methods Thirty-eight patients with MM in our hospital were selected and randomly divided into observation group and control group with 19 cases in each. The observation group was treated with PAD regimen and the control group was treated with VAD regimen (vincristine+doxorubicin+dexamethasone) . Clinical efficacy and adverse reaction were compared between the two groups. Results The effective rate and total effective rate of the observation group were 52.63%and 78.95%respectively, which were significantly higher than those of the control group ( 0.05) . Conclusion PAD regimen could improve the clinical effect of treating patients with MM, and the adverse reactions can be tolerated. It is safe and worthy of clinical application.